Abstract
Background: Herpes simplex virus type 1 causes recurrent herpes labialis, a common disease afflicting up to 40% of adults worldwide. A randomized, double–blind trial was conducted to compare the effectiveness & the patient tolerance of topically applied 0.5% zinc sulphate suspension with those of a placebo in the treatment of herpes simplex lesion. Patients & Methods: Sixty patients were enrolled in this study. The effectiveness & symptomatic relief of pain were recorded and Fisher exact test were used. Results: The zinc sulphate group showed significantly complete healing (p=0.001) than the placebo group & pain free during the follow-up period. The zinc sulphate group showed significantly better than the placebo group during the follow-up period. The safety that has been recorded of the drug were satisfactory, there is no pain with zinc sulphate group, no side effects. Conclusion: Topically applied 0.5% zinc sulphate suspension is an effective drug for the treatment of herpes simplex lesion in a short period with pain less.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
